File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Investigational drugs for atopic dermatitis

TitleInvestigational drugs for atopic dermatitis
Authors
Issue Date2018
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid
Citation
Expert Opinion on Investigational Drugs: authoritative analysis of R&D trends, 2018, v. 27, p. 637-647 How to Cite?
AbstractIntroduction: Many novel medications and herbal medicines have claimed efficacy on atopic dermatitis (AD). Areas covered: This review covers evidence on efficacy of topical and oral forms of novel and investigational drugs. Topical agents include emollients, phosphodiesterase E4 (PDE4) inhibitors, and topical herbs. There is little evidence that ceramides or natural moisturizing factors provide relief in AD. PDE4 inhibitors have shown promise as an effective topical treatment for mild-to-moderate AD with minimal adverse events, and dupilumab as an effective subcutaneous agent for the treatment of moderate-to-severe AD in adult patients with little adverse effects. However, only preliminary data are available for dupilumab in children with AD. The long-term effects of dupilumab are also not known. Potential new systemic treatments include a number of herbal concoctions. Expert opinion: Randomized, double-blind placebo-controlled trials (RCTs) have demonstrated topical PDE4 inhibitors are effective and safe in the treatment of both children and adults with AD but further evaluations are needed. RCTs have also shown that subcutaneous dupilumab is an effective and safe agent for the treatment of AD in adults. Long-term effects of these topical and systemic investigational drugs are currently unavailable. Regarding herbal medications, scientific methods are often flawed and objective evidence is lacking. KEYWORDS: Atopic dermatitis, Chinese medicine, crisaborole, dupilumab, eczema, herbs, investigational drugs, PDE4
Persistent Identifierhttp://hdl.handle.net/10722/264245
ISSN
2019 Impact Factor: 5.081
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHon, KL-
dc.contributor.authorLeung, AKC-
dc.contributor.authorLeung, TNH-
dc.contributor.authorLee, VWY-
dc.date.accessioned2018-10-22T07:51:51Z-
dc.date.available2018-10-22T07:51:51Z-
dc.date.issued2018-
dc.identifier.citationExpert Opinion on Investigational Drugs: authoritative analysis of R&D trends, 2018, v. 27, p. 637-647-
dc.identifier.issn1354-3784-
dc.identifier.urihttp://hdl.handle.net/10722/264245-
dc.description.abstractIntroduction: Many novel medications and herbal medicines have claimed efficacy on atopic dermatitis (AD). Areas covered: This review covers evidence on efficacy of topical and oral forms of novel and investigational drugs. Topical agents include emollients, phosphodiesterase E4 (PDE4) inhibitors, and topical herbs. There is little evidence that ceramides or natural moisturizing factors provide relief in AD. PDE4 inhibitors have shown promise as an effective topical treatment for mild-to-moderate AD with minimal adverse events, and dupilumab as an effective subcutaneous agent for the treatment of moderate-to-severe AD in adult patients with little adverse effects. However, only preliminary data are available for dupilumab in children with AD. The long-term effects of dupilumab are also not known. Potential new systemic treatments include a number of herbal concoctions. Expert opinion: Randomized, double-blind placebo-controlled trials (RCTs) have demonstrated topical PDE4 inhibitors are effective and safe in the treatment of both children and adults with AD but further evaluations are needed. RCTs have also shown that subcutaneous dupilumab is an effective and safe agent for the treatment of AD in adults. Long-term effects of these topical and systemic investigational drugs are currently unavailable. Regarding herbal medications, scientific methods are often flawed and objective evidence is lacking. KEYWORDS: Atopic dermatitis, Chinese medicine, crisaborole, dupilumab, eczema, herbs, investigational drugs, PDE4-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eid-
dc.relation.ispartofExpert Opinion on Investigational Drugs: authoritative analysis of R&D trends-
dc.rightsExpert Opinion on Investigational Drugs: authoritative analysis of R&D trends. Copyright © Informa Healthcare.-
dc.titleInvestigational drugs for atopic dermatitis-
dc.typeArticle-
dc.identifier.emailLeung, TNH: leungnht@hku.hk-
dc.identifier.authorityLeung, TNH=rp02256-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/13543784.2018.1494723-
dc.identifier.scopuseid_2-s2.0-85051664062-
dc.identifier.hkuros293898-
dc.identifier.volume27-
dc.identifier.spage637-
dc.identifier.epage647-
dc.identifier.isiWOS:000441641300001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats